DOCSLIB.ORG

||||||III US005578599A United States Patent (19) 11 Patent Number: 5,578,599 Diani Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
||||||III US005578599A United States Patent (19) 11 Patent Number: 5,578,599 Diani Et Al ||||||III US005578599A United States Patent (19) 11 Patent Number: 5,578,599 Diani et al. (45) Date of Patent: Nov. 26, 1996 54). STIMULATION OF HAIR GROWTH WITH 5,026,691 6/1991 Kligman et al. ........................ 514/171 NNE AND A SOREDUCTASE FOREIGN PATENT DOCUMENTS 0285382A2 10/1988 European Pat. Off. ....... A61K 31/58 T5 Inventors: Arthur R. Diani, Mattawan; Allen E. 3615396A 11/1987 Germany ....................... A61K 07/06 Buhl; Heinrich J. Schostarez, both of 1305017A 12/1989 Japan ....... ... A61K 07/06 Portage, all of Mich. WO87/00427 1/1987 WIPO ............................ A16K 07/06 73) Assignee: The Upjohn Company, Kalamazoo, Primary Examiner-Marianne M. Cintins Mich. Assistant Examiner-M. Moezie Attorney, Agent, or Firm-Donald L. Corneglio 22 Filed: Jan. 20, 1995 An improved method and composition for promoting hair growth in mammals for treating various forms of alopecia or Related U.S. Application Data male pattern baldness comprising the concomitant adminis 63 continuation of set No. 9451, filed as PCTus91.05170, ration of potassium channel openers, such asninoxidl, Jul. 29, 1991, abandoned, which is a continuation of Ser. No. cromakalim, pinacidil, or a compound selected frown the 565,777, Aug. 10, 1990, abandoned. classes of s-triazine, thiane-1-oxide, benzopyran and pyri dinopyran compounds; and a 50-reductase inhibitors, 173 51) Int. Cl.6 ......................... A61K 31/505; Alk 31/44 (N-tert-butylcarbamoyl)-4-aza-5-O-androst-1-en-3-one. The (52) U.S. Cl. ............................................. 514/275; 514/284 method comprises administering an effective amount of the 58) Field of Search ...................................... 514/284, 275 potassium channel opener and administering an effective O amount of the 173-(N-tert-butylcarbamoyl)-4-aza-5-O-an 56) References Cited drost-1-en-3-one whereby the promotion of hair growth is U.S. PATENT DOCUMENTS increase over the sole administration of the potassium chan nel opener. 4,139,619 2/1979 Chidsey, III .............................. 424/45 4,596,812 6/1986 Chidsey, III et al. .. ... 54/256 4,684,635 8/1987 Orentreich et al. ..................... 514/170 4 Claims, No Drawings 5,578,599 1 2 STIMULATION OF HAIR GROWTH WITH 50-reductase inhibitors. Androgen receptor blockers inter MINOXOL AND A SO-REDUCTASE fere with the binding of androgens, testosterone and dihy INHIBITOR drotestosterone (DHT), to their receptors, while 50-reduc tase inhibitors prevent the conversion of testosterone into DHT. The clinical use of androgen blockers, such as cypro CROSS-REFERENCE TO RELATED terone acetate, in men is complicated with systemic effects APPLICATIONS on normal sexual function. This is not the case in women, where these agents are utilized. Burke, B.M., Cunliff, W.J., This application is a continuation of U.S. Ser. No. 08/009, Br. J. Dermatol., 112, 124 (1985); Dawber, R. P. R., Sonnex, 451, filed 27 Jan. 1993, abandoned; which was a continua T., Ralfs, I., Br. J. Dermatol, Suppl. 107, 20 (1982). The tion of International Patent Application No. PCT/US91/ 10 other class of antiandrogens are the 5o-reductase inhibitors. 05170, filed 29 Jul. 1991; which was a continuation of U.S. These compounds block action of 5o-reductase and thus Ser. No. 07/565,777, filed 10 Aug. 1990, abandoned. reduce the level of DHT in the peripheral tissue. Rittmaster, BACKGROUND OF THE INVENTION R. S, Stoner, E., Thompson, D. L., Nance, D., Lasseter, K. The present invention relates to improved methods and C., J. Androl., 10, 259 (1989). Brooks, J. R., Berman, C., compositions for promoting hair growth by the concomitant 15 Primka, R. L., Reynolds, G. F., Rasmusson, G. H., Steroids, administration of a potassium channel opener such as 47, 1 (1986). Rittmaster, R. S., Uno, H., Povar, M. L., J. minoxidil, cromakalim, pinacidil, or a compound selected Clin, Endocrinol. Metab., 65, 188 (1987) have shown that from the classes of potassium channel openers such as topical treatment of periadolescent stumptail macaque mon S-triazine derivatives, benzopyran derivatives, pyridinopy eys with the 50-reductase inhibitor 4-MA prevented the ran derivatives and thiane-1-oxide compounds; and a 5o-re 20 progression of baldness normally observed in this species. ductase inhibitors, 173-(N-tert-butylcarbamoyl)-4-aza-5-o- Similar studies in humans have not been reported. androst-1-en-3-one. The coupling of hair growth stimulation with potassium Since the discovery that minoxidil could promote hair channel activation has been inferred from literature reports growth and was useful in the treatment of androgenetic 25 of several vasodilators, minoxidil (through its metabolite alopecia commonly known as "male pattern baldness' (U.S. minoxidil sulfate), pinacidil, and diazoxide, which cause Pat. Nos. 4,596,812; 4,139,619), alopecia areata, and bald varying degrees of hypertrichosis upon oral administration. ing in females, effort has been directed toward attempts to Zins, G. R., Clin. Dermatoll, 6, 132 (1988); Goldberg, M.R., improve upon the sole use of a topical minoxidil composi J. Cardiovasc. Pharmacol., 12(Suppl. 2), S41 (1988); Okun, tion by incorporating other active ingredients, for example 30 R., Russell, R. P., Wilkson, W. R., Arch Inter. Meal., 112, the combinations of minoxidil/hydrocortisone and minoxi 886 (1963). It is also known in the an that topical minoxidil dil/retinoids (DE 3827467-A). is an effective treatment for andogentic alopecia. The Another approach has been to attempt to identify and mechanism by which these compounds, minoxidil (through quantify the biological mechanisms responsible for the its metabolite minoxidil sulfate), pinacidil, and diazoxide, initiating and controlling hair growth at the follicular level 35 dilate vascular smooth muscle has been reported to be via and intervening with therapeutic agents which stimulate hair the opening (activation) of potassium channels. Robertson, growth. It is well known in the an that the onset of puberty D. W., Steinberg, M. I., J. Med. Chem., 33, 1529 (1990). results in changes in endocrine levels which result in, among Thus potassium channel openers are useful in the treatment other changes, the stimulation of facial hair growth (males), of androgenetic alopecia. axillary hair growth (males and females), and pubic hair The surprising and unexpected result, and the subject of growth (males and females). One class of compounds impli this invention, is the synergistic effect observed when both cated in these effects are the androgens. 17B-(N-tert-butylcarbamoyl)-4-aza-5-o-androst-1-en-3-one Androgens appear to play a major role in the development and minoxidil, a potassium channel opener, are utilized to and progression of androgenetic alopecia (male pattem stimulate or promote hair growth in a statistically significant baldness). Rittmaster, R. S., Clin. Dermatol, 6, 122 (1988). 45 fashion when compared to each drug alone. This was demonstrated in humans, in that prepubertally INFORMATION DISCLOSURE STATEMENT castrated men do not develop male pattern baldness. Hamil ton, J. B., Am. J. Anat, 71, 451 (1942). In the skin, and Topical minoxidil has been shown to be an effective presumably in the follicle, the effector androgen is dihyr treatment for male pattern baldness as described in U.S. Pat. dotestosterone (DHT), the product of the enzymatic conver 50 Nos. 4,596,812 and 4,139,619. The utilization of 17B-(N- sion of testosterone to DHT by the enzyme 5o-reductase. tert-butylcarbamoyl)-4-aza-5-O-androst-1-en-3-one for the Ebling, F. J. Clin. Endocrinol. Metab., 15,319 (1986); Price, treatment of androgenetic alopecia has been disclosed in V. H. Arch. Dermatol., 111, 1496 (1975). Additional evi European Patent Application 285382 A2. The use of com dence for DHT's role stems from reports that men with male binations of androgen receptor blocking agent (antiandro pattern baldness have elevated 5o-reductase levels in the 55 gen) and 5o-reductase inhibitors (not 17 B-(N-tert-butylcar hair follicles and skin of the frontal scalp and that men with bamoyl)-4-aza-5-O-androst-1-en-3-one) has been disclosed a 50-reductase deficiency do not develop male pattern in U.S. Pat. No. 4,684,635. The combination of minoxidil baldness. Bingham, K. D., Shaw, D. A., J. Endocrinol, 57, and an androgen receptor blocking agent for the treatment of 111 (1973); Schweikert, H. U., Wilson, J. D., J. Clin. male pattern baldness has also been disclosed in Patent Endocrinol. Metab., 385, 811 (1974). Antiandrogen therapy 60 Applications DE 3615-396-A and WO 8700-427-A. The offers a potential intervention to the treatment of male combination of minoxidil and a 50-reductase inhibitor for pattern baldness in men, and in women where it has been the treatment of male pattern baldness has also been dis suggested that elevated androgen levels are responsible for closed in Japanese Patent Application JA 1305-017-A. the appearance of male pattern baldness. Rittmaster, R. S., SUMMARY OF THE INVENTION Lofiaux, D. L., Ann. Intern. Med., 106, 95 (1987). This class 65 of compounds, the antiandrogens, have been subdivided into In one aspect, the subject invention is directed toward an two major catagories, the androgen receptor blockers and the improved method for promoting hair growth in mammals 5,578,599 3 4 comprising the administration of a potassium channel et al., J. Org. Chem, 40,3304 (1975). Related compounds opener in an effective amount and the administration of are sulfoxypyrimidinium, -pyridinium, and -triazinium 173-(N-tert-butylcarbamoyl)-4-aza-5-O-androst-1-en-3-one which are described in U.S. Pat. No. 4,287,338 herein in an effective amount whereby hair growth is increased over incorporated by reference. Hereinafter, the term "minoxidil' the sole administration of the potassium channel opener. The means any of the various forms of 6-amino-1,2-dihydro routes of administration for either component can be by any hydroxy-2-imino-4-pipefidinopyrimidine, derivatives and of various means, preferably orally, topically or any com analogs thereof.
Load more

Recommended publications
  • Molecular Mechanisms Underlying Ketamine-Mediated Inhibition Of
    Anesthesiology 2005; 102:93–101 © 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Molecular Mechanisms Underlying Ketamine-mediated Inhibition of Sarcolemmal Adenosine Triphosphate- sensitive Potassium Channels Takashi Kawano, M.D.,* Shuzo Oshita, M.D.,† Akira Takahashi, M.D.,‡ Yasuo Tsutsumi, M.D.,* Katsuya Tanaka, M.D.,§ Yoshinobu Tomiyama, M.D.,࿣ Hiroshi Kitahata, M.D.,# Yutaka Nakaya, M.D.** Background: Ketamine inhibits adenosine triphosphate-sen- sensitive channel pore.3 These channels, as metabolic sitive potassium (KATP) channels, which results in the blocking sensors, are associated with such cellular functions as of ischemic preconditioning in the heart and inhibition of va- insulin secretion, cardiac preconditioning, vasodilata- sorelaxation induced by KATP channel openers. In the current 4–7 Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/102/1/93/357819/0000542-200501000-00017.pdf by guest on 27 September 2021 study, the authors investigated the molecular mechanisms of tion, and neuroprotection. ketamine’s actions on sarcolemmal KATP channels that are re- In cardiac myocytes, intravenous general anesthetics, associated by expressed subunits, inwardly rectifying potas- such as ketamine racemate, propofol, and thiamylal, di- sium channels (Kir6.1 or Kir6.2) and sulfonylurea receptors 8–10 rectly inhibit native sarcolemmal KATP channels. Al- (SUR1, SUR2A, or SUR2B). though these observations suggest that intravenous an- Methods: The authors used inside-out patch clamp configura- tions to investigate the effects of ketamine on the activities of esthetics may impair the endogenous organ protective reassociated Kir6.0/SUR channels containing wild-type, mutant, mechanisms mediated by KATP channels, the possibility or chimeric SURs expressed in COS-7 cells.
    [Show full text]
  • Biomol Average and SD Table S1.Xlsx
    Compound GliNS1 G179NS G166NS average, n=5 STD average, n=3 STD average, n=3 STD INTRACELLULAR CALCIUM Antibiotic A-23187 0.00 0.00 0.10 0.07 0.15 0.14 INTRACELLULAR CALCIUM Ryanodine 1.04 0.14 1.03 0.03 1.03 0.03 INTRACELLULAR CALCIUM Cyclopiazonic acid 1.01 0.06 0.88 0.05 0.92 0.06 INTRACELLULAR CALCIUM Gingerol 1.00 0.06 0.91 0.01 1.01 0.06 INTRACELLULAR CALCIUM Thapsigargin 0.00 0.01 0.00 0.00 0.10 0.12 INTRACELLULAR CALCIUM TMB-8 0.89 0.07 0.91 0.05 0.94 0.03 INTRACELLULAR CALCIUM Dantrolene 0.91 0.08 0.98 0.05 0.94 0.01 CALCIUM CHANNELS Amiloride 1.01 0.07 1.01 0.04 1.03 0.05 CALCIUM CHANNELS Benzamil 0.83 0.08 0.83 0.12 0.96 0.04 CALCIUM CHANNELS BAY K-8644 0.93 0.13 0.93 0.09 1.07 0.14 CALCIUM CHANNELS Diltiazem 0.96 0.07 0.99 0.12 0.94 0.14 CALCIUM CHANNELS L-cis-Diltiazem 0.91 0.17 1.01 0.12 0.95 0.12 CALCIUM CHANNELS Flunarizine 0.85 0.08 1.00 0.06 0.85 0.05 CALCIUM CHANNELS FPL-64176 0.99 0.11 0.95 0.07 1.05 0.05 CALCIUM CHANNELS Nifedipine 1.06 0.17 0.95 0.12 1.03 0.09 CALCIUM CHANNELS Nimodipine 1.05 0.06 0.95 0.03 1.06 0.17 CALCIUM CHANNELS Nitrendipine 0.99 0.07 0.96 0.10 1.04 0.09 CALCIUM CHANNELS SDZ-202791 R(-) 1.01 0.08 0.92 0.06 1.01 0.08 CALCIUM CHANNELS SKF-96365 0.73 0.05 0.70 0.11 0.69 0.04 CALCIUM CHANNELS Tetrandrine 0.47 0.07 0.76 0.16 0.87 0.20 CALCIUM CHANNELS Verapamil 1.01 0.02 0.89 0.07 1.06 0.20 CALCIUM CHANNELS Methoxy Verapamil 0.93 0.14 0.96 0.07 0.93 0.13 CALCIUM CHANNELS Bepridil 0.70 0.16 0.92 0.15 0.84 0.14 CALCIUM CHANNELS Amiodarone 0.32 0.12 0.58 0.07 0.48 0.23 CALCIUM CHANNELS YS035 1.00 0.16
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Label-Free Cell Phenotypic Profiling Decodes the Composition And
    OPEN Label-free cell phenotypic profiling SUBJECT AREAS: decodes the composition and signaling POTASSIUM CHANNELS SENSORS AND PROBES of an endogenous ATP-sensitive Received potassium channel 28 January 2014 Haiyan Sun1*, Ying Wei1, Huayun Deng1, Qiaojie Xiong2{, Min Li2, Joydeep Lahiri1 & Ye Fang1 Accepted 24 April 2014 1Biochemical Technologies, Science and Technology Division, Corning Incorporated, Corning, NY 14831, United States of Published America, 2The Solomon H. Snyder Department of Neuroscience and High Throughput Biology Center, Johns Hopkins University 12 May 2014 School of Medicine, Baltimore, Maryland 21205, United States of America. Current technologies for studying ion channels are fundamentally limited because of their inability to Correspondence and functionally link ion channel activity to cellular pathways. Herein, we report the use of label-free cell requests for materials phenotypic profiling to decode the composition and signaling of an endogenous ATP-sensitive potassium should be addressed to ion channel (KATP) in HepG2C3A, a hepatocellular carcinoma cell line. Label-free cell phenotypic agonist Y.F. (fangy2@corning. profiling showed that pinacidil triggered characteristically similar dynamic mass redistribution (DMR) com) signals in A431, A549, HT29 and HepG2C3A, but not in HepG2 cells. Reverse transcriptase PCR, RNAi knockdown, and KATP blocker profiling showed that the pinacidil DMR is due to the activation of SUR2/ Kir6.2 KATP channels in HepG2C3A cells. Kinase inhibition and RNAi knockdown showed that the pinacidil * Current address: activated KATP channels trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling. The results are the first demonstration of a label-free methodology to characterize the Biodesign Institute, composition and signaling of an endogenous ATP-sensitive potassium ion channel.
    [Show full text]
  • Thiruttu Tuomittur
    THIRUTTUUS009782416B2 TUOMITTUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,782 ,416 B2 Cowen (45 ) Date of Patent: Oct. 10 , 2017 ( 54 ) PHARMACEUTICAL FORMULATIONS OF 4 , 880 , 830 A 11/ 1989 Rhodes POTASSIUM ATP CHANNEL OPENERS AND 4 ,894 , 448 A 1 / 1990 Pelzer 5 ,063 , 208 A 11/ 1991 Rosenberg et al . USES THEREOF 5 , 284 ,845 A 2 / 1994 Paulsen 5 ,356 ,775 A 10 / 1994 Hebert et al . (71 ) Applicant: Essentialis , Inc. , Carlsbad , CA (US ) 5 ,376 , 384 A 12 / 1994 Eichel et al. 5 , 378 , 704 A 1 / 1995 Weller, III (72 ) Inventor: Neil Madison Cowen , Carlsbad , CA 5 , 399 , 359 A 3 / 1995 Baichwal 5 ,415 , 871 A 5 / 1995 Pankhania et al . (US ) 5 ,629 , 045 A 5 / 1997 Veech 5 , 733 , 563 A 3 / 1998 Fortier (73 ) Assignee : Essentialis , Inc. , Redwood City , CA 5 , 744 , 594 A 4 / 1998 Adelman et al . (US ) 5 , 965 ,620 A 10 / 1999 Sorgente et al . 6 ,022 , 562 A 2 /2000 Autant et al . 6 , 140 , 343 A 10 / 2000 Deninno et al . ( * ) Notice : Subject to any disclaimer , the term of this 6 , 146 ,662 A 11/ 2000 Jao et al . patent is extended or adjusted under 35 6 , 197, 765 B1 3 / 2001 Vardi et al. U . S . C . 154 (b ) by 0 days . 6, 197, 976 B1 3 / 2001 Harrington et al . 6 , 225, 310 B1 5 / 2001 Nielsen et al. (21 ) Appl. No. : 14 / 458 ,032 6 , 255 , 459 B1 7 / 2001 Lester et al . 6 , 277, 366 B1 8 / 2001 Goto et al .
    [Show full text]
  • Niflumic Acid Hyperpolarizes Smooth Muscle Cells Via Calcium-Activated Potassium Channel in Spiral Modiolar Artery of Guinea Pigs1
    Acta Pharmacol Sin 2008 Jul; 29 (7): 789–799 Full-length article Niflumic acid hyperpolarizes smooth muscle cells via calcium-activated potassium channel in spiral modiolar artery of guinea pigs1 Li LI2,3, Ke-tao MA3,4, Lei ZHAO3, Jun-qiang SI3,4,5, Zhong-shuang ZHANG3, He ZHU3, Jing LI3 2Departmeng of Pharmacology, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China; 3Labo- ratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University Medical College, Xinjiang 832002, China; 4Fundamental Medical School of Wuhan University, Wuhan 430071, China Key words Abstract spiral modiolar artery; smooth muscle cells; Aim: The influence of niflumic acid (NFA), a Cl– channel antagonist, on the mem- 2+ niflumic acid; hyperpolarization; Ca - brane potentials in smooth muscle cells (SMC) of the cochlear spiral modiolar activated potassium channels; cochlea artery (SMA) in guinea pigs was examined. Methods: The intracellular recording 1This work was supported by the National and whole-cell recording technique were used to record the NFA-induced re- Natural Science Foundation of China (No sponse on the acutely-isolated SMA preparation. Results: The SMC had 2 stable 30460043); the Scientific and Technological Program for Overseas Personnel, the but mutually convertible levels of resting potentials (RP), that is, one was near –45 Ministry of Personnel, China (2006); and the mV and the other was approximately –75 mV, termed as low and high RP, Key Program of Scientific and Technological respectively. The bath application of NFA could cause a hyperpolarization in all Research, the Ministry of Education, China (Local Universities; No 207134). the low RP cells, but had little effect on high RP cells.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • Inhibitory Mechanism of Nicorandil on Catecholamine Secretion from the Rat Adrenal Medulla
    2006년 2월 박사학위논문 Inhibitory Mechanism of Nicorandil on Catecholamine Secretion from the Rat Adrenal Medulla 조선대학교 대학원 의학과 이은숙 Inhibitory Mechanism of Nicorandil on Catecholamine Secretion from the Rat Adrenal Medulla 흰쥐 부신수질에서 니코란딜의 카테콜아민 분비작용에 대한 억제기전 2006년 2월 일 조선대학교 대학원 의학과 이은숙 Inhibitory Mechanism of Nicorandil on Catecholamine Secretion from the Rat Adrenal Medulla 지도교수 임임임 동동동 윤윤윤 이이이 논문을 의학박사 학위 신청논문으로 제출함. 2005 년 10 월 일 조조조선대학교조선대학교 대학원 의학과 이은숙 이 은 숙의 박사학위논문을 인준함 위원장 서울 대학교 교수 인인인 위위위 원원원 전남 대학교 교수 인인인 위위위 원원원 조선 대학교 교수 인인인 위위위 원원원 조선 대학교 교수 인인인 위위위 원원원 조선 대학교 교수 인인인 2005 년 12 월 29 일 조선대학교 대학원 CONTENTS KOREAN ABSTRACT ---------------------------------------------------------------------- I. INTRODUCTION ---------------------------------------------------------------------------- II. MATERIALS AND METHODS ----------------------------------------------------------- Experimental Procedure ------------------------------------------------------------------------------ Perfusion of Adrenal Gland -------------------------------------------------------------------------- Drug Administration --------------------------------- -------------------------------------------------- Collection of Perfusate -------------------------------------------------------------------------------- Measurement of Catecholamines ------------------------------------------------------------------ Statistical Analysis ------------------------------------------------------------------------------------- Drugs and Their Sources -----------------------------------------------------------------------------
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • KATP Channel Openers Facilitate Glutamate Uptake by Gluts in Rat Primary Cultured Astrocytes
    Neuropsychopharmacology (2008) 33, 1336–1342 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org KATP Channel Openers Facilitate Glutamate Uptake by GluTs in Rat Primary Cultured Astrocytes 1,2 1,2 1 1 1 ,1 Xiu-Lan Sun , Xiao-Ning Zeng , Fang Zhou , Cui-Ping Dai , Jian-Hua Ding and Gang Hu* 1 Laboratory of Neuropharmacology, Department of Anatomy, Histology & Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, P.R. China Increasing evidence, including from our laboratory, has revealed that opening of ATP sensitive potassium channels (KATP channels) plays the neuronal protective roles both in vivo and in vitro. Thus K channel openers (KCOs) have been proposed as potential ATP neuroprotectants. Our previous studies demonstrated that K channels could regulate glutamate uptake activity in PC12 cells as well as ATP in synaptosomes of rats. Since glutamate transporters (GluTs) of astrocytes play crucial roles in glutamate uptake and KATP channels are also expressed in astrocytes, the present study showed whether and how KATP channels regulated the function of GluTs in primary cultured astrocytes. The results showed that nonselective KCO pinacidil, selective mitochondrial KCO diazoxide, novel, and blood–brain barrier permeable KCO iptakalim could enhance glutamate uptake, except for the sarcolemmal KCO P1075. Moreover pinacidil, + diazoxide, and iptakalim reversed the inhibition of glutamate uptake induced by 1-methyl-4-phenylpyridinium (MPP ). These potentiated effects were completely abolished by mitochondrial K blocker 5-hydroxydecanoate. Furthermore, either diazoxide or iptakalim could ATP + inhibit MPP -induced elevation of reactive oxygen species (ROS) and phosphorylation of protein kinases C (PKC). These findings are the first to demonstrate that activation of KATP channel, especially mitochondrial KATP channel, improves the function of GluTs in astrocytes due to reducing ROS production and downregulating PKC phosphorylation.
    [Show full text]
  • Altered ATP-Sensitive Potassium Channels May Underscore Obesity-Trig- Gered Increase in Blood Pressure1
    Acta Pharmacol Sin 2008 Oct; 29 (10): 1167–1174 Full-length article Altered ATP-sensitive potassium channels may underscore obesity-trig- gered increase in blood pressure1 Li-hong FAN2,4, Hong-yan TIAN2,4, Ai-qun MA2,5, Zhi HU2, Jian-hua HUO2, Yong-xiao CAO3 2Department of Cardiology, The First Affiliated Hospital of Xi-an Jiaotong University School of Medicine, Xi-an 710061, China; 3Department of Phar- macology, Xi’an Jiaotong University School of Medicine, Xi-an 710061, China Key words Abstract ATP-sensitive potassium channel; obesity- Aim: To determine whether ATP-sensitive potassium channels are altered in hypertension; electrophysiology; aorta; VSMC from arotas and mesenteric arteries of obese rat, and their association with mesenteric artery obesity-triggered increase in blood pressure. Methods: Obesity was induced 1 Project supported by the National Natural by 24 weeks of high-fat diet feeding in male Sprague–Dawley rats. Control rats Science Foundation of China (No 30370677). were fed with standard laboratory rat chow. Blood pressure and body weight of 4 These two authors contributed equally to this work. these rats were measured every 4 weeks. At the end of 24 weeks, KATP channel- 5 Correspondence to Prof Ai-qun MA. mediated relaxation responses in the aortas and mesenteric arteries, KATP channel Phn/Fax 86-29-8526-1809. current, and gene expression were examined, respectively. Results: Blood pres- E-mail [email protected] sure and body weight were increased in rats fed with high-fat diet. KATP channel- Received 2007-12-26 mediated relaxation responses, currents, and KATP expression in VSMC of both Accepted 2008-04-22 aortas and mesenteric arteries were inhibited in these rats.
    [Show full text]
  • Synthesis and Vasorelaxant Effect of 9-Aryl-1, 8-Acridinediones As
    Iranian Journal of Pharmaceutical Research (2012), 11 (1): 229-233 Copyright © 2012 by School of Pharmacy Received: January 2010 Shaheed Beheshti University of Medical Sciences and Health Services Accepted: July 2010 Original Article Synthesis and Vasorelaxant Effect of 9-aryl-1,8-acridinediones as Potassium Channel Openers in Isolated Rat Aorta Mohsen Imenshahidia, Farzin Hadizadeha,b*, Asieh Firoozeh-Moghadama, Mahmoud Seifia, Atefeh Shirinbaka and Mohammad Bagher Gharedaghia aPharmacy Faculty, Mashhad University of Medical Sciences, Mashhad, Iran. bBiotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Abstract ATP-sensitive potassium (KATP) channel openers have a relaxation effect due to the lower cellular membrane potential and inhibit calcium influx. There has been considerable interest in exploring KATP channel openers in the treatment of various diseases such as cardiovascular, cerebrovascular, and urinary system disease and premature labor. The purpose of this study was to synthesize 3,3,6,6-tetramethy l-9-aryl-octahydro-1,8-acridindiones and investigate their effects on vascular potassium channels and mechanism of induced relaxations on phenylephrine- induced contractile responses in isolated rings of rat aortic smooth muscle. In this study, four new derivatives of 3,3,6,6-tetramethy l-9-aryl-octahydro-1,8-acridindione [2a-d] were synthesized by the reaction of 5, 5-dimethyl-1,3-cyclohexanedione with an aromatic aldehyde, 2-alkylthio-1-(4-fluorobenzyl)-5-formylimidazole or 3-substituted benzaldehyde, in the presence of ammonia in methanol. Their effects on vascular potassium channels and mechanism of induced relaxations on phenylephrine-induced contractile responses in isolated rat aorta were investigated. Minoxidil was used as a standard potassium channel opener and Glibenclamide was used as a standard potassium channel blocker.
    [Show full text]